<DOC>
	<DOCNO>NCT02015416</DOCNO>
	<brief_summary>This Phase I , multi-center , multiple ascend dose study evaluate clinical safety immune response IDC-G305 inject intramuscularly patient unresectable metastatic cancer . IDC-G305 immunotherapy consist recombinant NY-ESO-1 antigen adjuvant , GLA-SE . The goal IDC-G305 stimulate body 's immune system fight spread growth cancer patient whose tumor include NY-ESO-1 protein . Patients melanoma , ovarian , renal cell non-small cell lung cancer may consider trial .</brief_summary>
	<brief_title>A Phase 1 Trial NY-ESO-1 With GLA-SE Patients With Unresectable Metastatic Cancer</brief_title>
	<detailed_description>This Phase 1 , open label , multicenter , multiple ascend dose trial IDC-G305 administer intramuscular injection 3+3 sequential dose escalation design . IDC-G305 immunotherapy consist recombinant NY-ESO-1 antigen adjuvant , GLA-SE . Patients unresectable , relapsed metastatic cancer low disease burden indolent disease course may consider trial . Tumors must express NY-ESO-1 gene signature tumor type study : melanoma , ovarian , sarcoma , non-small cell lung breast cancer . Each three dose level cohort treat contingent upon absence dose limit toxicity ( DLT ) acceptable safety data precede cohort . Initially , three patient schedule receive IDC-G305 dose level cohort . Dose escalation contingent upon assessment safety data obtain initial injection . Patients evaluate baseline regular interval safety immune response . Both cellular humoral immunogenicity explore .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Confirmed diagnosis melanoma , ovarian cancer , sarcoma , breast cancer nonsmall cell lung cancer ( NSCLC ) Unresectable , relapse and/or metastatic cancer minimal low disease burden . Disease may may measurable rapidly progressive . Inadequate response , relapse and/or unacceptable toxicity one prior systemic , surgical , radiation cancer therapy , except patient NSCLC breast cancer must experience inadequate response and/or unacceptable toxicity two prior systemic , surgical , radiation cancer therapy . Cancer express NYESO1 ≥ 18 year age Life expectancy ≥ 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ECG without evidence clinically significant arrhythmia ischemia Negative pregnancy test female childbearing potential Pregnant nursing Vaccine therapy direct NYESO1 time past investigational therapy within three week prior IDCG305 dose Significant immunosuppression Cancer chemotherapy , GCSF GMCSF within three week prior first study treatment Significant autoimmune disease Myocardial infarction within six month treatment , active cardiac ischemia Grade III IV heart failure Inadequate hematology chemistry profile History cancer within three year Active , concurrent recent infection , include tuberculosis , hepatitis B , hepatitis C HIV Uveal melanoma Brain metastasis consider unstable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Breast cancer</keyword>
</DOC>